

Prospective phenotyping and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

NCT06855329

Status RECRUITING
Sponsor University of Massachusetts, Worcester
Enrollment 500 participants

Key Eligibility Criteria

Inclusion (4)

- Age 18-80 years with a diagnosis of non-IPF fibrosing ILD due to CTD-ILD, fHP, or non-IPF IIP based on central review
- Diagnosis of Fibrotic ILD as determined by site investigator.
- Willingness to comply with study procedures and follow-up.
- Provide written informed consent.

Exclusion (8)

- Site diagnosis of fibrosing ILD ≥ 5 years prior to Visit 1 (Screening and Baseline Visit).
- Minimal ILD, defined as reticular opacities and/or ground-glass opacities without architectural distortion (traction bronchiolectasis/bronchiectasis or honeycombing) affecting $< 5\%$ of the lung on centralized evaluation of HRCT at Visit 1 (Screening and Baseline Visit). High quality historical chest HRCT may be used if performed within 90 days prior to Visit 1.
- Extent of emphysema $\geq 15\%$ of total lung volume or greater than extent of fibrosis based on central, qualitative assessment of HRCT at Visit 1. High quality historical chest HRCT may be used if performed within 90 days prior to Visit 1.
- Active malignancy within one year prior to Visit 1 (except for non-melanoma skin cancer requiring local treatment).
- Inability to complete full PFT (spirometry and DLCO) at Visit 1. Historical PFT may be used if performed within 90 days prior to Visit 1.

... and 3 more (see full listing online)

Locations (13 total)

University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Texas Southwestern, Dallas, Texas, United States
... and 10 more locations